We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current BIOA market cap is 164.9M. The company's latest EPS is USD -1.7812 and P/E is -2.61.
Quarter End | Sep 2024 |
---|---|
USD (US$) | |
Total Revenue | 0 |
Operating Income | -24.75M |
Net Income | -23.41M |
Year End 31 December 2023 | 2023 |
---|---|
USD (US$) | |
Total Revenue | 0 |
Operating Income | -48.4M |
Net Income | -63.85M |
Quarter End | Sep 2024 |
---|---|
USD (US$) | |
Total Assets | 337.38M |
Total Liabilities | 23.63M |
Total Equity | 313.75M |
Year End 31 December 2023 | 2023 |
---|---|
USD (US$) | |
Total Assets | 25.92M |
Total Liabilities | 66.6M |
Total Equity | -173.4M |
Market Cap | 164.9M |
Price to Earnings Ratio | -2.61 |
Price to Sales Ratio | 0 |
Price to Cash Ratio | 7.7 |
Price to Book Ratio | -4.1 |
Dividend Yield | - |
Shares Outstanding | 35.85M |
Average Volume (1 week) | 3.15M |
Average Volume (1 Month) | 953.05k |
52 Week Change | -79.56% |
52 Week High | 26.62 |
52 Week Low | 4.23 |
Spread (Intraday) | 0.01 (0.22%) |
Company Name | BioAge Labs Inc |
Address |
131 continental drive newark, delaware 19713 |
Website | https://www.bioagelabs.com |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions